To The Moon

Sign Up

Hao1

Looking for an adventure with bountiful outcomes!

    • Hao1Hao1
      ·12-02
      $Plug Power(PLUG)$   Why This Is Extremely Bullish ✔ 1. NASA partnership = validation NASA would not work with a scammy, low-quality or unreliable company. This means: Plug’s hydrogen tech meets strict standards Plug is a serious player This is a reputation boost that NO marketing campaign can buy. --- ✔ 2. NASA consumes huge volumes of liquid hydrogen NASA uses hydrogen for: Rocket propulsion Space launch infrastructure Fuel cell systems Cryogenic testing Even small volumes mean massive revenue relative to Plug's size. This is NOT a “trial”. NASA doesn’t trial fuel. NASA orders fuel. --- ✔ 3. Stable, government-backed contract Government contracts are: Long term Predictable High-margin This gives Plug: Recurrin
      6171
      Report
    • Hao1Hao1
      ·11-21
      $INCANNEX HEALTHCARE LTD(IXHL)$ This is very important news, and it is one of the BEST pieces of clinical news IXHL has released in a long time. Let me break it down carefully and simply for you: ⭐ 1. Phase 2 data CONFIRMS the drug actually works This line is HUGE: “IHL-42X showed up to an 83% reduction in AHI in Phase 2 trials.” AHI = the number of times your breathing stops per hour. 👉 83% improvement is extremely strong. 👉 This means many patients had almost normal breathing during sleep. This is NOT small improvement. This is life-changing level improvement. For sleep apnea patients, this is VERY meaningful. --- ⭐ 2. This makes IHL-42X one of the most promising oral treatments in the world Today, sleep apnea treatment options are mostly: CPAP (hard to tolerate) Surgery (risky) Devices

      Incannex Healthcare reports Phase 2 data showing IHL-42X reduces AHI in obstructive sleep apnoea

      Incannex Healthcare Inc. reported quarter-end cash of $73.3 million, a net loss of $6.4 million, and operating expenses of $6.8 million, supporting at least twelve months of financial runway. During the period, the company advanced its clinical programs, including significant progress with IHL-42X for obstructive sleep apnoea, which showed up to 83.0% reduction in Apnoea-Hypopnoea Index in Phase 2 trials, and PSX-001, which demonstrated meaningful anxiety reduction in Phase 2. Preparations are underway for FDA interactions and further clinical studies.Disclaimer: This news brief was created by Public Technologies using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via Newsfile on November 20, 2025, and is solely
      Incannex Healthcare reports Phase 2 data showing IHL-42X reduces AHI in obstructive sleep apnoea
      338Comment
      Report
    • Hao1Hao1
      ·11-21
      $INCANNEX HEALTHCARE LTD(IXHL)$ This is very important news, and it is one of the BEST pieces of clinical news IXHL has released in a long time. Let me break it down carefully and simply for you: ⭐ 1. Phase 2 data CONFIRMS the drug actually works This line is HUGE: “IHL-42X showed up to an 83% reduction in AHI in Phase 2 trials.” AHI = the number of times your breathing stops per hour. 👉 83% improvement is extremely strong. 👉 This means many patients had almost normal breathing during sleep. This is NOT small improvement. This is life-changing level improvement. For sleep apnea patients, this is VERY meaningful. --- ⭐ 2. This makes IHL-42X one of the most promising oral treatments in the world Today, sleep apnea treatment options are mostly: CPAP
      442Comment
      Report
    • Hao1Hao1
      ·11-19
      $Pony AI Inc(PONY)$   🚀 Pony AI Inc (PONY): A Next-Generation Autonomous Driving Leader Poised for Significant Growth Pony AI is quickly emerging as one of the most compelling innovators in the global autonomous driving industry. Backed by world-class technology, strong partnerships, and expanding commercial operations, the company is now transitioning from early-stage development to real-world deployment at scale — a shift that could unlock tremendous long-term value for investors. --- 🌟 1. Industry Leadership With Proven Technology Pony AI is one of the very few companies worldwide with: Fully driver-free (Level 4) robotaxi operations in major cities such as Beijing, Guangzhou, Shenzhen, and Shanghai. Over 30 million kilometers of autonomou
      258Comment
      Report
    • Hao1Hao1
      ·11-06
      $Plug Power(PLUG)$   🌿 Plug Power: At the Forefront of the Hydrogen Economy Plug Power is far more than a speculative clean‐tech stock; it’s positioning itself as a foundational player in the global transition to green hydrogen and fuel‐cell technologies. With urgency growing around decarbonisation, Plug’s role may be increasingly central. --- 🔧 Why It Stands Out Real-World Deployments, Not Just Promises Plug has moved beyond concept to execution: its GenEco electrolyzer systems are operational in Europe, including at large-scale sites. That kind of proof of tech in service is a strong differentiator. Massive Opportunity Pipeline The company has cited a multi‐billion-dollar pipeline of electrolyzer and hydrogen
      7124
      Report
    • Hao1Hao1
      ·11-06
      $Pony AI Inc(PONY)$   🚀 Pony.ai Inc. (PONY) – Driving the Future of Autonomous Mobility 🏁 Overview Pony.ai is emerging as one of the world’s most advanced and credible autonomous driving companies. Founded in 2016, the company has rapidly transitioned from research to real-world commercial operations — deploying robotaxi services across Beijing, Guangzhou, Shenzhen, and expanding into Singapore, Dubai, and Europe. With deep partnerships with Toyota, Uber, Tencent, and major Chinese OEMs, Pony.ai has positioned itself at the forefront of the global driverless revolution. --- ⚙️ Business Momentum & Achievements Gen-7 Robotaxi Breakthrough: The company’s Gen-7 platform has achieved a 70% reduction in production cost and integrates automotive
      1.04K3
      Report
    • Hao1Hao1
      ·10-07
      $Plug Power(PLUG)$  
      437Comment
      Report
    • Hao1Hao1
      ·10-02
      $INCANNEX HEALTHCARE LTD(IXHL)$ If the IXHL discovered an oral cure for chronic obstructive sleep apnea (OSA), the impact would be enormous—medically, socially, and economically. Here’s how it might play out: 🌍 Medical Impact 1. End of CPAP dependency – Millions of patients would no longer need to use CPAP machines or other invasive devices every night. 2. Reduced surgeries – Procedures like UPPP (uvulopalatopharyngoplasty), jaw advancement, or hypoglossal nerve stimulation would see a huge decline. 3. Better overall health – Untreated OSA contributes to hypertension, heart disease, stroke, diabetes, and even dementia. A cure could lower risks across all of these. 4. Sleep quality revolution – Millions would finally get restorative sleep, re
      1.93K4
      Report
    • Hao1Hao1
      ·10-01
      $INCANNEX HEALTHCARE LTD(IXHL)$ 📊 Incannex Healthcare (IXHL) – Opportunity at Current Levels Incannex Healthcare (NASDAQ: IXHL) closed recently at $0.45, a level that coincides with key technical support. The company’s FY2025 results highlight both challenges and progress in its development path: Revenue: $0.086M (+617% YoY), primarily from expansion of rehabilitation services. Operating expenses: $23.9M (↓21% YoY), reflecting tighter cost control. R&D investment: $10.8M, demonstrating continued focus on advancing the pipeline. Net loss: $46.9M, consistent with heavy R&D activity as trials progress. Although IXHL has not yet generated material revenue from product sales, management is advancing late-stage clinical programs, including ther
      1.98K5
      Report
    • Hao1Hao1
      ·08-27
      $Nokia Oyj(NOK)$   Nokia (NYSE: NOK) has recently gained investor attention following a manager’s insider purchase disclosure (Uitto’s transaction under EU Market Abuse Regulation). Insider buying is generally interpreted as a strong vote of confidence from leadership, signaling that management views the stock as undervalued and poised for growth. 🔹 Financial Strength and Outlook Revenue Growth: Nokia reported €5.3B in Q2 2025 revenue, demonstrating resilience in its Networks and Cloud segments. While the telecom equipment sector remains competitive, Nokia’s cost optimization initiatives have preserved healthy margins. Profitability: Operating margin improved to 8.9%, reflecting disciplined execution despite macr
      2.14K3
      Report
      • empty
        No followers yet
       
       
       
       

      Most Discussed